Physician profile
Maher Kassis
NPI 1912968603
$28,246.29
in general payments reported to CMS, 2019-2025
31 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $217 · 2021: $735 · 2022: $18K · 2023: $5,487 · 2024: $1,944 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,562 · Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,562.25 |
| Food and Beverage | $1,158.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $25,268.19 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $448.85 | 2019-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $430.14 | 2019-2023 | Xarelto |
| Pfizer INC. | $367.14 | 2019-2023 | |
| Abbvie INC. | $291.09 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $284.61 | 2019-2022 | |
| Amgen INC. | $242.34 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $141.95 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $108.89 | 2019-2022 | |
| Lilly USA, LLC | $84.76 | 2019-2023 | Mounjaro, Amyvid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.00 | 2019-2023 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $60.71 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.09 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $49.39 | 2022-2023 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $35.46 | 2023 | Gemtesa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $32.19 | 2019 | |
| Dexcom, INC. | $28.13 | 2022-2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $27.82 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $27.73 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $22.49 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.84 | 2023 | Ultomiris |
| Pulmonx Corporation | $17.44 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Avanir Pharmaceuticals, INC. | $16.40 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.64 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $14.65 | 2023 | |
| Insulet Corporation | $14.40 | 2019 | |
| Evoke Pharma, INC. | $13.63 | 2024 | |
| Nestle Healthcare Nutrition INC. | $13.60 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.93 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.67 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Kassis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.